{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T09:37:00Z","timestamp":1768642620187,"version":"3.49.0"},"reference-count":31,"publisher":"BMJ","issue":"6","funder":[{"DOI":"10.13039\/501100001729","name":"Stiftelsen fr Strategisk Forskning","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001729","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2017,3,15]]},"published-print":{"date-parts":[[2017,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess incidence of condyloma after two doses of quadrivalent human papillomavirus (qHPV) vaccine, by time since first vaccine dose, in girls and women initiating vaccination before age 20 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Register-based nationwide open cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Sweden.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Girls and women initiating qHPV vaccination before age 20 years between 2006 and 2012. The study cohort included 264 498 girls, of whom 72 042 had received two doses of qHPV vaccine and 185 456 had received all three doses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcome measure<\/jats:title>\n                    <jats:p>Incidence rate ratios (IRRs) of condyloma estimated by time between first and second doses of qHPV in months (m) and age at vaccination, adjusted for attained age.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>For girls first vaccinated with two doses before the age of 17 years, the IRR of condyloma for 0\u20133 months between the first and second doses was 1.96 (95% CI 1.43 to 2.68) as compared with the standard three-dose schedule. The IRRs were 1.27 (95% CI 0.63 to 2.58) and 4.36 (95% CI 2.05\u2009to 9.28) after receipt of two doses with 4\u20137 months and 8+ months between doses, respectively. For women first vaccinated after the age of 17 years, vaccination with two doses of qHPV vaccine and 0\u20133 months between doses was associated with an IRR of 2.12 (95% CI 1.62\u2009to 2.77). For an interval of 4\u20137 months between doses, the IRR did not statistically significantly differ to the standard three-dose schedule (IRR=0.81, 95% CI 0.36\u2009to 1.84). For women with 8+ months between dose 1 and dose 2 the IRR was 3.16 (95% CI 1.40\u2009to 7.14).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A two-dose schedule for qHPV vaccine with 4\u20137 months between the first and second doses may be as effective against condyloma in girls and women initiating vaccination under 20 years as a three-dose schedule. Results from this nationwide study support immunogenicity data from clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2016-015021","type":"journal-article","created":{"date-parts":[[2017,6,9]],"date-time":"2017-06-09T21:03:55Z","timestamp":1497042235000},"page":"e015021","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":12,"title":["Timing of two versus three doses of quadrivalent HPV vaccine and associated effectiveness against condyloma in Sweden: a nationwide cohort study"],"prefix":"10.1136","volume":"7","author":[{"given":"F","family":"Lamb","sequence":"first","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Herweijer","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Ploner","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Uhnoo","sequence":"additional","affiliation":[{"name":"Public Health Agency of Sweden, Solna, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Sundstr\u00f6m","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Spar\u00e9n","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Arnheim-Dahlstr\u00f6m","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2017,6,8]]},"reference":[{"key":"2025121408435718000_7.6.e015021.1","doi-asserted-by":"crossref","unstructured":"Schiller JT , Lowy DR . Raising expectations for subunit vaccine. J\u00a0Infect Dis 2015;211.doi:10.1093\/infdis\/jiu648","DOI":"10.1093\/infdis\/jiu648"},{"key":"2025121408435718000_7.6.e015021.2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.1625"},{"key":"2025121408435718000_7.6.e015021.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.11.059"},{"key":"2025121408435718000_7.6.e015021.4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.407"},{"key":"2025121408435718000_7.6.e015021.5","doi-asserted-by":"publisher","DOI":"10.4161\/hv.28022"},{"key":"2025121408435718000_7.6.e015021.6","doi-asserted-by":"publisher","DOI":"10.4161\/hv.7.12.18322"},{"key":"2025121408435718000_7.6.e015021.7","unstructured":"WHO. Human papillomavirus vaccines: who position paper,. 2014 http:\/\/www.who.int\/wer\/2014\/wer8943.pdf?ua=1."},{"key":"2025121408435718000_7.6.e015021.8","unstructured":"European Medicines Agency. Assessment report Gardasil, 2014."},{"key":"2025121408435718000_7.6.e015021.9","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ364"},{"key":"2025121408435718000_7.6.e015021.10","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-009-9350-y"},{"key":"2025121408435718000_7.6.e015021.11","unstructured":"World Health Organisation. International classification of disease. Tenth Revision 2010."},{"key":"2025121408435718000_7.6.e015021.12","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djt032"},{"key":"2025121408435718000_7.6.e015021.13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.95"},{"key":"2025121408435718000_7.6.e015021.14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0412.2010.01066.x"},{"key":"2025121408435718000_7.6.e015021.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2015.02.005"},{"key":"2025121408435718000_7.6.e015021.16","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1080\/21645515.2015.1058458","article-title":"Evaluation of the immunogenicity of the quadrivalent HPV vaccine using 2 versus 3 doses at month 21: an epidemiological surveillance mechanism for alternate vaccination schemes","volume":"12","author":"Hern\u00e1ndez-\u00c1vila","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"2025121408435718000_7.6.e015021.17","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.vaccine.2013.09.007","article-title":"Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial","volume":"32","author":"Krajden","year":"2014","journal-title":"Vaccine"},{"key":"2025121408435718000_7.6.e015021.18","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2015.1065363"},{"key":"2025121408435718000_7.6.e015021.19","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.CAPR-13-0203"},{"key":"2025121408435718000_7.6.e015021.20","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-015-0178-4"},{"key":"2025121408435718000_7.6.e015021.21","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S1473-3099(11)70324-3","article-title":"Assessment of herd immunity from human papillomavirus vaccination","volume":"11","author":"Bogaards","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"2025121408435718000_7.6.e015021.22","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1080\/21645515.2016.1160978","article-title":"An exploration of individual- and population-level impact of the 2-dose HPV vaccination schedule in pre-adolescent girls","volume":"12","author":"Donken","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"2025121408435718000_7.6.e015021.23","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(10)70225-5"},{"key":"2025121408435718000_7.6.e015021.24","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu370"},{"key":"2025121408435718000_7.6.e015021.25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g1458"},{"key":"2025121408435718000_7.6.e015021.26","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-11-227"},{"key":"2025121408435718000_7.6.e015021.27","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1002\/ijc.30035","article-title":"Quadrivalent HPV vaccine effectiveness against high-grade cervical lesions by age at vaccination: a population-based study","volume":"138","author":"Herweijer","year":"2016","journal-title":"Int J Cancer"},{"key":"2025121408435718000_7.6.e015021.28","doi-asserted-by":"publisher","DOI":"10.1177\/1403494816653669"},{"key":"2025121408435718000_7.6.e015021.29","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw354"},{"key":"2025121408435718000_7.6.e015021.30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0134185","article-title":"Population-Based Cohort Study","volume":"10","author":"Herweijer","year":"2015","journal-title":"PLoS One"},{"key":"2025121408435718000_7.6.e015021.31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g7584"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2016-015021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T16:44:07Z","timestamp":1765730647000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2016-015021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":31,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2017,6,8]]},"published-print":{"date-parts":[[2017,6]]}},"alternative-id":["10.1136\/bmjopen-2016-015021"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2016-015021","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6]]}}}